A Yale-led research team developed a new RNA therapy, delivered through the nose, to treat mice infected with West Nile Virus. The innovative approach reduced the virus in the brain, allowing the immune system to destroy the virus and develop long-term protection against West Nile Virus disease, the researchers said.
The findings, published in Cell Host & Microbe, may represent a breakthrough strategy for treating West Nile Virus after virus invasion of the brain and the central nervous system, noted senior author Priti Kumar, M.D., associate professor of infectious disease at Yale School of Medicine.
There are no approved vaccines or effective therapies for West Nile Virus disease, a mosquito-borne condition. While many infected individuals have no symptoms, others — particularly the very young and older adults — can develop severe neurological problems and even die from the disease. The sporadic nature of the disease makes it exceedingly difficult for testing and implementing vaccines, said Kumar.
To investigate a possible new therapy to treat West Nile Virus disease, Kumar and her colleagues focused on a small “interfering” RNA molecule developed in her lab. The RNA acts against multiple mosquito-borne flaviviruses. To direct the RNA to infected cells, they packaged it in a peptide derived from the rabies virus, which is able to enter nerve cells. The final step was to the deliver the therapy through the nose where it could bypass natural barriers protecting the brain.
With this novel approach, the researchers found that the therapy reduced the virus in the brain, preventing harm to nerve cells. The treated mice had a 90% survival rate a few days after infection compared to mice treated with placebo. Significantly, noted the researchers, in the surviving mice, the immune system cleared the virus throughout the body, and also enabled long-term protection against future exposure.
The researchers concluded that the treatment offers both a promising late-stage therapy and lifelong immunity. It “prevents pathology in the brain and gives the mice a chance to develop a robust immune response,” said Kumar.
While the anatomy of the murine nose differs from that of humans, the researchers plan to study the therapy further with the hope it will be broadly applicable. “In translation, it should be an effective strategy for people,” she said.
If that is the case, the intranasal RNA therapy could theoretically be developed for treatment of other mosquito-borne diseases, such as St. Louis encephalitis, Japanese encephalitis, and perhaps Zika, the researchers noted.
The Latest on: RNA therapy
via Google News
The Latest on: RNA therapy
- Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer on November 12, 2018 at 11:29 pm
Ad-RTS-hIL-12 plus veledimex is an investigational gene therapy designed to induce and control the production of human interleukin 12 (hIL-12) that activates the immune system and recruits cancer-figh... […]
- Why you need to know about RNA therapy and its potential to revolutionize disease treatment on November 5, 2018 at 5:22 am
Although you may have heard of gene therapy, you probably haven’t heard of RNA therapy. Unlike gene therapy, which provides new DNA to cells, RNA therapy modifies or provides ribonucleic acid ... […]
- This RNA-based technique could make gene therapy more effective on October 16, 2018 at 8:03 am
Delivering functional genes into cells to replace mutated genes, an approach known as gene therapy, holds potential for treating many types of diseases. The earliest efforts to deliver genes to ... […]
- RNA Technology Driving the New Wave of Therapeutics, 2018 Market Report - ResearchAndMarkets.com on September 26, 2018 at 7:51 am
This Drug Discovery TOE depicts trends across RNA technology driving a new wave of therapeutics. Different, stable, non-Immunogenic mRNA therapies, targeted RNAi technologies and therapeutics, CAR T-c... […]
- Alnylam’s RNA therapy Onpattro bags EU nod on August 31, 2018 at 2:47 am
Alnylam’s RNAi therapeutic Onpattro has been approved for use in Europe to treat Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in adults with Stage 1 or Stage 2 polyneuropa... […]
- Use of HIV RNA Expression Inhibitors May Restore Immune Function in HIV-Infected Individuals on cART on August 26, 2018 at 5:00 pm
A new study by BUSM researchers suggests that use of HIV RNA expression inhibitors as adjunct therapy might diminish atypical inflammation and restore immune function in HIV-infected individuals on co... […]
- Researchers develop a novel RNA-based therapy to target West Nile Virus on March 29, 2018 at 9:20 am
A Yale-led research team developed a new RNA therapy, delivered through the nose, to treat mice infected with West Nile Virus. The innovative approach reduced the virus in the brain, allowing the immu... […]
- Ionis Is A Buy On RNA Platform Pipeline on March 7, 2018 at 5:38 am
including CAR-T and gene therapy. Another approach that should net investors extraordinary returns is RNA-based antisense and RNAi (interference) therapies. Ionis Pharmaceuticals (IONS) is one of the ... […]
via Bing News